Text Size
Trial record 6 of 19 for:    Open Studies | "Chickenpox"
Previous Study | Return to List | Next Study

Efficacy of TCA Effect on Varicella Atrophic Scars

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Shaheed Beheshti Medical University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Shaheed Beheshti Medical University
ClinicalTrials.gov Identifier:
NCT00422539
First received: January 16, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
  Purpose

This study aims to determine the efficacy of 70% trichloroacetic acid on atrophic scars of varicella


Condition Intervention Phase
Atrophic Varicella Scar
 Drug: 70% trichloroacetic acid
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shaheed Beheshti Medical University:

Primary Outcome Measures:
  • Objective Clearance(before and after photographies were taken)

Secondary Outcome Measures:
  • Subjective Clearance(according to the patients satisfaction)
  • Adverse effects(assessed by clinician as erythema, pigmentary changes, scaring)

Estimated Enrollment: 100
Study Start Date: March 2006
Detailed Description:

high concentration trichloroacetic acid peeling has been shown to be effective in treating and flattening the atrophic acne scars. According to the lack of an effective and low cost therapy for removing these relative common and nuisance lesions; We aimed to answer that whether we could achieve the same results from 70% TCA on atrophic varicella scars.

  Eligibility

Ages Eligible for Study:   15 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Atrophic varicella scar on face

Exclusion Criteria:

  • Active varicella infection
  • Active Herpetic infection
  • Previous history of keloid formation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00422539

Contacts
Contact: Behrooz Barikbin, M.D. 98-21-22744393 ext 5 bbarikbin@yahoo.com

Locations
Iran, Islamic Republic of
Skin Research Center, Shohada-e Tajrish Hospital, shaheed Beheshti Medical University Recruiting
Tehran, Iran, Islamic Republic of, 198994148
Sponsors and Collaborators
Shaheed Beheshti Medical University
Investigators
Study Chair: Parviz Toossi, M.D. Skin Research Center of Shaheed Beheshti medical University
Principal Investigator: Behrooz Barikbin, M.D. Skin Research Center of Shaheed Beheshti Medical Universty
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00422539     History of Changes
Other Study ID Numbers: SRC-BBA-1385-6-1
Study First Received: January 16, 2007
Last Updated: January 16, 2007
Health Authority: Iran: Ministry of Health

Keywords provided by Shaheed Beheshti Medical University:
trichloroacetic acid
varicella scar

Additional relevant MeSH terms:
Chickenpox
Herpes Zoster
Atrophy
Cicatrix
Herpesviridae Infections
 DNA Virus Infections
Virus Diseases
Pathological Conditions, Anatomical
Fibrosis
Pathologic Processes

ClinicalTrials.gov processed this record on May 22, 2013